Search results
Added:
1 week ago
ACC.26 - In this expert interview filmed at ACC.26 in New Orleans, Prof. Felipe Martínez discusses how late-breaking heart failure data are reshaping contemporary pharmacological management. The conversation focuses on new spironolactone results, advanced hemodynamic strategies in HFpEF, and the expanding role of cardiometabolic therapies, including GLP‑1 receptor agonists, in optimising outcomes…
View more
Added:
1 month ago
In this episode of Arrhythmia Academy's Journal Club, Dr David Duncker (Hannover Heart Rhythm Center, DE) is joined by Dr Marat Fudim (Duke University, US) to examine the critical early-risk period following heart failure diagnosis and the emerging role of wearable cardioverter defibrillators in sudden cardiac death prevention.The discussion centres on findings from the SCD-PROTECT study, a 19…
View more
Targeting Obesity for Heart Failure
Added:
3 months ago
Review Article
Added:
1 year ago
ACC 25 - Findings of the MIGHTy-Heart study shows no difference between mobile integrated healthcare and a traditional transitions of care coordinator approach in 30-day all-cause readmissions or health status.Dr Ruth Masterson Creber (Columbia University, New York, US) joins us onsite at ACC to discuss the findings from MIGHTy-Heart, a comparative effectiveness study that evaluated two different…
View more
Added:
4 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more
Added:
7 months ago
ESC Congress 2025 - In this video, Dr Michelle Kittleson (Cedars-Sinai Heart Institute, US) outlines the hot-line data from the congress that are expected to have an impact on clinical practice in the heart failure space.Trials covered in detail include:REBOOT-CNIC: Beta-Blockers after Myocardial Infarction without Reduced Ejection FractionBETAMI-DANBLOCK: Beta-Blockers after Myocardial…
View more
Recognising Undiagnosed Heart Failure in Women
Video Series
Added:
7 months ago
ESC Congress 2025 - Vericiguat did not reduce the risk of cardiovascular mortality and hospitalization in heart failure with reduced ejection fraction, fewer cardiovascular deaths and all-cause deaths were observed.Host, Dr Harriette Van Spall (McMaster University, CA) is joined on-site at ESC Congress 2025 in Madrid by Dr Faiez Zannad (University of Lorraine, FR) to discuss pivotal results from…
View more
Added:
7 months ago
ESC Congress 2025 - Dr Harriette Van Spall (McMaster University, Canada) sits down with Professor Michael Borger (University of Leipzig Heart Center, Germany), Co-Chair of the newly released 2025 ESC/EACTS Guidelines for the Management of Valvular Heart Disease.The new guidelines bring together the latest evidence and expert consensus on how to diagnose, evaluate, and treat patients with valvular…
View more
Added:
5 months ago
Navigate the strategic complexities of transcatheter mitral valve replacement in multivalvular disease with Dr Kimberly HolstThis presentation, part of Women As One's comprehensive Structural Interventions track, provides a systematic framework for approaching multivalvular heart disease. The presentation establishes the foundational principle of strategic intervention sequencing in high-risk…
View more